Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome

Sacrococcygeal Teratoma Clinical Trial

— Currarino  

Official title:

Characterization of At-risk Population and Prognosis Factors for SACRO-coccygeal Teratoma in CURRARINO Syndrome. A Clinical, Molecular and Pathological Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00780117
• Other study ID #: P070305
• Status: Completed
• Phase: N/A
• First received: October 24, 2008
• Last updated: July 25, 2012
• Start date: June 2008
• Est. completion date: December 2011

Study information

• Verified date: July 2012
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Contribute to support hypothesis of relationships between genes involve in oncogenesis and those involve in embryological development.

Description:

CURRARINO syndrome (CS) (OMIM 176450) is a rare congenital disease described in 1981, as the association of, at least, three main clinical features: typical sacral malformation (sickled-shape sacrum or total sacral agenesis below S2), hindgut anomalies and pre-sacral tumor. To date, neurological defects, as tethered cord and/or lipoma of the filum or the conus, are up lighted to be as a fourth major clinical sign.In half of cases, CS is ascribed to heterozygous mutations of the HLXB9 gene (or MNX1 gene, OMIM 142994) located at 7q36, with an autosomal dominant mode of inheritance. The HLXB9 gene is involved in motoneurons and caudal development of the embryo. However, genetic heterogeneity is suspected, since patients without HLXB9 mutation harbour subtle phenotypic variations. Presently, no other locus has been identified. The pre-sacral tumor develops in almost 80% of CS. When it is a teratoma (30% of cases), it may turn into malignancy in 1 to 4 % of cases, according to literature. As far as we know, no clinical, molecular or pathological marker is operational to predict tumoral evolution and give any prognosis. Major aim of this study is to find out any correlation between clinical signs, constitutional and somatic genetic anomalies of HLXB9 gene and other candidate genes, and/or pathological features and tumoral evolution in CS. Evaluation of the pre-sacral tumor evolution is based on local recurrence or distance metastasis after surgical removal. Annual serum alpha-foeto-protein level monitoring is also performed, as the unique marker of teratoma.This study specifically required annual clinical examination and lumbar-sacral MRI imaging, three blood samples at inclusion and an annual blood sample.This multicentric study will last for at least 6 years. Eighty patients will be included and follow up for at least 3 years. Finally, this study may help identify a group of at-risk patients for tumor development and malignant transformation if pre-sacral teratoma. It will also help define objective clinical, radiological, molecular, pathological and/or biological criteria for long lasting survey. In general, it may also contribute to support hypothesis of close relationships between genes involve in oncogenesis and those involve in embryological development.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: December 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• At least 1 out of the 4 major signs of CURRARINO syndrome:

1. Sacral agenesis

2. Hindgut malformation or chronic constipation

3. Presacral tumor and/or

4. TETHECORD syndrome and/or lipoma of the filum or the conus

• Anomaly genotyping HLXB9 without clinical expression

Exclusion Criteria:

• Opposition to sign informed consent agreement

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• CURRARINO Syndrome
• Digestive System Abnormalities
• Presacral Mass
• Sacrococcygeal Teratoma
• Syndrome
• Syringomyelia
• Teratoma

Locations

Country	Name	City	State
France	Hôpital Necker-Enfants Malades Pediatric Surgery Department	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Annual lumbar-sacral MRI is performed		one year	No
Secondary	Pathological tumoral tissue analysis after surgical removal		3 years	No
Secondary	Annual serum alpha-foeto protein level monitoring		one year	No